OS Therapies Incorporated OSTX
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -42.64%
- 1 year
- -50.43%
5D +0.0544 (+6.29%)
- Market cap
- 42.00M
- EPS (ttm)
- -1.08
- Shares out
- 21.24M
- Forward P/E
- 2.57
- YTD return
- -42.64%
- 1-year return
- -50.43%
- 50-day average
- 2.72
- Volume
- 489.73K
- Avg volume
- 720.93K
- Open
- 0.8094
- Previous close
- 0.8204
- Day's range
- 0.7901 – 0.8625
- 52-week range
- 0.681 – 2.24
- Price target
- 12.67 (+1477.4%)
Key statistics
- 200-day average
- 3.11
- Enterprise value
- 62.55M
- Total cash
- 94.92K
- Total debt
- 16.70M
Fundamental scorecard
2 of 25 checks passed on OSTX’s reported financials
2of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | Maxim Group | init | — | Buy |
| Oct 3, 2024 | EF Hutton | main | Buy | Buy |
| Sep 16, 2024 | EF Hutton | main | Buy | Buy |
| Sep 3, 2024 | EF Hutton | init | — | Buy |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ostherapies.com
News
12 Health Care Stocks Moving In Wednesday's After-Market Session OS Therapies Says FDA's Shelving Of Commissioner's National Priority Voucher Has No Impact On Its Rare Pediatric Disease PRV Prospects
OS Therapies Initiates CMAA Process With UK MHRA For Herlystic In Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma; Expects To Complete CMAA Process Later In Q4 Of 2026
Your note
Sign in to keep a note on OSTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Millennium Management Llc | 0.28% | 60,435 | 228.44K | Sep 29, 2024 |
| CM Management, LLC | 0.24% | 50,000 | 189.00K | Sep 29, 2024 |
| Delta Investment Management, LLC | 0.09% | 18,081 | 68.35K | Sep 29, 2024 |
| HRT Financial LP | 0.08% | 17,576 | 66.44K | Sep 29, 2024 |
| Virtu Financial LLC | 0.05% | 10,045 | 37.97K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 3,806 | 14.39K | Sep 29, 2024 |
